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with only soft tissues. If structural stability is required,
however, either autogenous tissue (such as fascia lata or
rib) or prosthetic material (such as the various meshes,
metals, or soft tissue patches) may be used. Little is
known of the morbidity, mortality, and long-term dura-
bility rates of prosthetic reconstruction after chest wall
resection. The purpose of this review was to evaluate
our results in patients undergoing prosthetic bony
reconstruction after chest wall resection.
Patients and methods
From January 1, 1977, to December 31, 1992, 197 patients
underwent chest wall resection and reconstruction with pros-
thetic material at the Mayo Clinic. The records of these
patients were analyzed for age, sex, preoperative conditions,
indications for treatment, type of operation, operative mor-
R econstruction of full-thickness defects of the chestwall is controversial. In small defects the skeletal
component can be ignored, and the defect can be closed
Objective: The purpose of this report is to evaluate our results in patients
who underwent prosthetic bony reconstruction after chest wall resec-
tion. Methods: We retrospectively reviewed all patients who underwent
chest wall resection and reconstruction with prosthetic material at the
Mayo Clinic. Results: From January 1, 1977, to December 31, 1992, 197
patients (109 male patients and 88 female patients) underwent chest
wall resection and reconstruction with prosthetic material. Median age
was 59 years (range, 11-86 years). The indication for resection was
recurrent chest wall malignancy in 65 patients (33.0%), primary chest
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bidity and mortality rates, late operation, and adjuvant out-
come. Follow-up data were obtained from the patients’ most
recent records and from correspondence with referring phys-
icians. The category operative deaths included both those
patients who died within the first 30 days after operation and
those who died later but during the same hospitalization.
Comparisons between groups were analyzed with a c 2 test
with a Yates correction applied to the P value. Two-way con-
tingency tables were used to determine which clinical factors
were associated with outcomes.
There were 197 patients (109 male patients and 88 female
patients). The median age was 59 years and ranged from 11
to 86 years. Associated conditions included long-term ciga-
rette smoking in 82 patients, prior radiation therapy in 41
patients, chronic obstructive pulmonary disease in 29
patients, prior chemotherapy in 27 patients, corticosteroid use
in 19 patients, and diabetes in 10 patients. The indication for
resection was recurrent chest wall malignancy in 65 patients
(33.0%), primary chest wall malignancy in 62 patients
(31.5%), contiguous lung cancer in 53 patients (26.9%), con-
tiguous breast cancer in 5 patients (2.5%), desmoid tumor in
5 patients (2.5%), an open draining wound in 3 patients
(1.5%), radiation necrosis in 2 patients (1.0%), and costo-
chondritis in 2 patients (1.0%).
Often both ribs and sternum were included in the chest
wall resection. The median number of ribs resected was 3
(range, 1-8 ribs). A partial sternectomy was performed in
46 patients (23.4%), and a total sternectomy was performed
in 7 patients (3.6%). A portion of the clavicle was removed
in 8 patients (4.1%), and 4 patients underwent partial resec-
tion of 1 or more vertebral bodies. Fifty-eight patients
(29.4%) underwent pulmonary resection, which included
lobectomy in 30 patients, pneumonectomy in 13 patients,
segmentectomy or wedge excision in 11 patients, and
bilobectomy in 4 patients. Other associated operations in-
cluded a mastectomy, bilateral removal of breast implants,
removal of a previously placed Marlex mesh (Bard
Cardiosurgery, Billerica, Mass), and a thymectomy in 1
patient each.
This review covers 2 time periods. Skeletal reconstruction
was achieved with Prolene mesh (PM; Ethicon, Inc,
Somerville, NJ) in 64 patients (32.5%) during the period from
1977 to 1986. A 2-mm thick polytetrafluoroethylene* (PTFE)
soft tissue patch was used in 133 patients (67.5%) from 1984
to 1992. These time periods reflect the senior surgeons’
(P.C.P. and P.G.A.) prosthetic material of choice for the inter-
val involved. Soft tissue coverage was achieved with trans-
posed muscle in 116 patients, local tissue only in 78 patients,
and omentum in 3 patients. Muscles transposed included
latissimus dorsi in 45 patients, pectoralis major in 44 patients,
serratus anterior in 15 patients, external oblique in 6 patients,
rectus abdominis in 4 patients, trapezius in 1 patient, and
internal oblique in 1 patient.
Results
The 2 groups of patients (PM and PTFE) were simi-
lar for age, diagnosis, previous treatment and associat-
ed conditions, extent of resection, hospitalization, and
follow-up. The proportion of women was significantly
higher in the PM group (P = .034). Postoperative com-
plication occurred in 91 patients (46.2%) (Table I).
Wound seromas occurred in 10 patients with PTFE and
in 4 patients with PM; none developed a wound infec-
tion. Twelve seromas were small and resolved, 6 spon-
taneously and 6 after repeated aspirations. The condi-
tion of the remaining 2 patients (both with PTFE)
required wound explorations and obliteration of the
cavity with eventual healing. Wound infections oc-
curred in 9 patients (5 patients with PM and 4 patients
with PTFE). The 3 patients who had a contaminated
wound before the operation experienced the develop-
ment of a postoperative infection. All 3 patients had
undergone chest wall reconstruction with PM; in each
patient, the PM was later removed, but at that point (13
to 64 days) the underlying lung had adhered to the
chest wall, preventing open pneumothorax. Thus no
further skeletal reconstruction was performed. In addi-
tion, the PM was removed in 2 other patients with
wound infections. In contrast, the wounds in the 4
patients with PTFE were opened, debrided, and packed
with gauze. All 4 wounds were closed by secondary
intent, and all wounds were healed by the time of hos-
pital dismissal. There were 8 operative deaths (mortal-
ity rate, 4.1%). All of the deaths occurred in patients
who had concurrent pulmonary resection.
Indications for lung resection were contiguous lung
cancer in 5 patients, contiguous breast cancer in 1
patient, metastatic carcinoma to the chest wall in 1
patient, and malignant fibrous histiocytoma in 1
patient. Cause of death was myocardial infarction in 3
patients, respiratory failure in 3 patients, pulmonary
embolus in 1 patient, and multiple organ failure in 1
*Gore-Tex patch; registered trade mark of W. L. Gore & Associates,
Inc, Flagstaff, Ariz.
Table I. Complications in 197 patients undergoing
prosthetic chest wall reconstruction
Complication N Percent
Respiratory 48 24.4
Seroma 14 7.1
Wound infection 9 4.6
Arrhythmia 5 2.5
Hemorrhage 4 2.0
Myocardial infarction 3 1.5
Prolonged air leak 2 1.0
Other 6 3.0
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patient. Median hospitalization for all 197 patients was
14 days (range, 2-76 days).
Follow-up was complete in 179 operative survivors
(94.7%) and ranged from 1 to 204 months (median, 26
months). Sixty-six patients (36.9%) are currently alive.
Cause of death in the remaining 113 patients was recur-
rent malignancy in 65 patients, causes unrelated to the
original chest wall condition in 15 patients, and
unknown in 33 patients. At last follow-up or at the time
of death, 127 patients (70.9%) had a well-healed,
asymptomatic chest wall. An additional 43 patients
(24.0%) initially also had a well-healed chest but sub-
sequently experienced chest wall local cancer recur-
rences. The status of the wound was unknown in the
remaining 8 patients.
The local cancer recurrence was breast carcinoma in
24 patients, chondrosarcoma in 5 patients, other sarco-
ma in 7 patients, lung carcinoma in 2 patients, desmoid
tumor in 2 patients, squamous cell carcinoma of the
skin in 1 patient, malignant pleural mesothelioma in 1
patient, and metastatic hypernephroma in 1 patient. Six
patients with local recurrence underwent reoperation at
a median of 18 months after the initial chest wall resec-
tion (range, 8-21 months). The chest wall was again
resected, and a PTFE patch was used for reconstruction
in all 6 patients. At follow-up, 4 of these patients who
underwent reoperation for local recurrence experienced
a second local recurrence; the remaining 2 patients
were asymptomatic with a well-healed chest wall.
None of the 9 patients who experienced a postoperative
wound infection had further evidence of infection. All
had a healed wound without drainage. One other patient
required reduction mammoplasty because of a breast
deformity attributed to the chest wall reconstruction.
Factors affecting long-term outcome were analyzed.
Preoperative chemotherapy and/or radiation therapy,
oral corticosteroid, diabetes, smoking history, presence
of chronic obstructive pulmonary disease, histologic
type, and type of prosthesis did not significantly affect
the incidence of seroma, wound infection, length of
hospitalization, local cancer recurrence, and other com-
plications. Similarly, the extent of rib or sternal resec-
tion had no effect on postoperative morbidity and
deaths. However, associated pulmonary resection had
an adverse effect on operative deaths (P = .0002).
Discussion
Defects of the chest wall almost always occur as a
result of neoplasm (primary or recurrent), radiation
injury, infection, or trauma. Chest wall defects pro-
duced by excision of most neoplasms result in loss of
the skeleton and frequently the overlying soft tissues as
well. Radiation injury, infection, and trauma produce
partial or full-thickness defects, depending on their
severity. Not uncommonly, various combinations of
these afflictions occur in the same patient, and man-
agement of these problems often becomes problematic.
The surgeon is eager to obtain wide margins and rid the
patient of all possible malignant, contaminated, or irra-
diated tissue while leaving a defect that can be closed
to maintain life itself. A thorough knowledge of recon-
structive techniques with a clear operative plan that
includes a “secondary or fallback” procedure, if possi-
ble, is most desirable. We believe that this dilemma is
best managed by the combined efforts of both a tho-
racic and plastic surgeon.1-5
Reconstruction of the bony chest wall is controver-
sial. Differences of opinion exist about who should
undergo reconstruction and what type of reconstruction
should be done.6-13 In general, all full-thickness skele-
tal defects that have the potential for paradox should be
reconstructed. The decision not to reconstruct the
skeleton depends on the size and location of the defect.
Defects less than 5 cm in greatest diameter anywhere
on the thorax are usually not reconstructed. Posterior
defects less than 10 cm likewise do not require recon-
struction because the overlying scapula provides sup-
port, unless they are located at the tip of the scapula
where entrapment of the scapula can occur during
movement of the arm.
The choice of prosthetic material is confusing.
Numerous prostheses exist, and all of them work rea-
sonably well.12,14 For the most part, the choice is based
on surgeon’s preference. We tend to use either PM or
PTFE and believe that both materials are contraindicat-
ed in contaminated wounds, unless the surgeon thinks
that the patient cannot undergo extubation without this
additional support. PM is more difficult than PTFE to
stretch and suture without wrinkles and surface irregu-
larities and does not achieve a watertight seal of the
pleural space. PTFE, in contrast, is much easier to
suture, stretch, and mold into the wound and provides
a barrier that prevents fluid and air from moving
between the pleural and subcutaneous space. We secure
the patch with heavy interrupted nonabsorbable
sutures, which are placed either through or around the
ribs. PTFE, however, must be 2-mm thick because the
1-mm thickness does not hold sutures well at the ten-
sion needed to stabilize the chest wall. For these rea-
sons PTFE became our prosthesis of choice in the mid
1980s. However, this review demonstrated that the use
of PTFE to reconstruct the chest wall did not translate
into a reduced rate of seromas, wound infections, and
other postoperative complications.
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Suction drains are more often used in conjunction
with muscle flaps, when dead space and raw surface are
significant. They are left in place usually until daily
drainage is less than 25 mL per drain. Small seromas
are best managed with observation because most will
resolve eventually. When the seromas are large or
symptomatic, aspiration under strict aseptic conditions
offers the best treatment option. Surgical obliteration of
the seroma cavity was rarely necessary in our experi-
ence. With this approach, none of the seromas in our
patients progressed to wound infections.
Early in our experience, several prostheses were
placed in contaminated wounds, which led to subse-
quent wound infections; the prostheses were removed
in all of these cases. As experience was gained, we
avoided placing a prosthesis in a contaminated wound,
and we became confident in leaving the prosthesis in
situ in a subsequent wound infection if the prosthesis
was incorporated by granulation tissue at the level of
insertion to the chest wall. Combining this approach
with intensive wound debridement and frequent dress-
ing changes, the prosthesis was salvaged in the last one
half of this review in all patients who experienced the
development of a wound infection. Equally as impor-
tant, none of these patients with salvaged prostheses
experienced the development of a late wound infection
or a draining sinus tract.
Soft tissue reconstraction with local tissue, if possi-
ble, offers the simplest and most practical method of
covering the prosthesis. If local tissue is not available,
muscle transposition is the tissue of choice for cover-
age, with the omentum being reserved as back-up if
muscle transposition has failed or if no muscle is avail-
able.1-2 Skin grafts are used where appropriate.
We conclude that chest wall resection and recon-
struction with prosthetic material will yield satisfactory
results in most patients and that little difference exists
between skeletal reconstruction with PM or PTFE. The
decision of which prosthesis to use remains the sur-
geon’s choice.
R E F E R E N C E S
1. Pairolero PC, Arnold PG. Thoracic wall defects: surgical man-
agement of 205 consecutive patients. Mayo Clin Proc 1986;61:
557-63.
2. Arnold PG, Pairolero PC. Chest-wall reconstruction: an account
of 500 consecutive patients. Plast Reconstr Surg 1996;98:804-10.
3. Arnold PG, Pairolero PC. Reconstruction of the radiated-dam-
aged chest wall. Surg Clin North Am 1989;69:1081-9.
4. Arnold PG, Pairolero PC. Surgical management of the radiated
chest wall. Plast Reconstr Surg 1986;77:605-12.
5. Arnold PG, Pairolero PC. Chest wall reconstruction: experience
with 100 consecutive patients. Ann Surg 1984;199:725-32.
6. Soysal O, Walsh GL, Nesbitt JC, et al. Resection of sternal
tumors: extent, reconstruction, and survival. Ann Thorac Surg
1995;60:1353-9.
7. McCormack P, Bains MS, Beattie EJ Jr, et al. New trends in
skeletal reconstruction after resection of chest wall tumors. Ann
Thorac Surg 1981;31:45-52.
8. Ryan MB, McMurtrey MJ, Roth JA. Current management of
chest-wall tumors. Surg Clin North Am 1989;69:1061-80.
9. McKenna RJ, McMurtrey MJ, Larson D, et al. A perspective on
chest wall resection in breast cancer patients. Ann Thorac Surg
1984;38:482-6.
10. Kroll SS, Walsh G, Ryan B, et al. Risks and benefits of using
Marlex mesh in chest wall reconstruction. Ann Plast Surg 1993;
31:303-6.
11. Economou SG, Southwick HW. The repair of thoracic wall
defects with sliding rib grafts. J Thorac Surg 1958;36:112-6.
12. McCormack PM. Use of prosthetic materials in chest wall recon-
struction: assets and liabilities. Surg Clin North Am 1989;69:965-
76.
13. McKenna RJ Jr, Mountain CF, McMurtrey MJ, et al. Current
techniques for chest wall reconstruction: expanded possibilities
for treatment. Ann Thorac Surg 1988;46:508-12.
14. Eschapasse H, Gaillard J, Henry E, et al. Chest wall tumors: sur-
gical management. In: Grillo HC, Eschapasse H, editors.
International trends in general thoracic surgery: major chal-
lenges. Philadelphia: WB Saunders; 1987. p. 292-307.
Discussion
Dr Erino A. Rendina (Rome, Italy). You and your col-
leagues have reported on a very large series of patients under-
going chest wall reconstruction by prosthetic material, which
might well be the largest clinical review of this problem
reported in the literature to date. Excellent follow-up was
obtained in almost 95% of the patients; however, the cause of
death is unknown in 33 of 113 patients. Do you think that this
information would alter our comprehension of the problem or
modify your conclusions? 
Patients who experienced wound infection were treated dif-
ferently in that those patients who had PM underwent
removal of the prosthesis, although those patients with PTFE
were treated conservatively. Also, in 3 cases preoperative
contamination led to postoperative infection. Would you
comment on these 2 issues? Would you recommend the use
of 1 specific prosthetic material when dealing with an infect-
ed operative field? 
Also, there is increasing evidence in the literature that the
omentum offers precious aid in the reconstruction of the chest
wall, yet it was used in only 3 patients. 
Finally, could you also comment on the present status of
rigid prosthetic material such as methyl methacrylate mesh,
which was not used in this series?
Dr Deschamps. Concerning the 33 patients for whom the
cause of death was unknown, we can assume that most of
those patients died of cancer. That is an operation that is
mainly palliative. If you look, we did not show any survival,
but many patients died of cancer within 5 years (secondary
cancer, breast cancer). Considering that this is a palliative
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procedure and that we have achieved a goal of palliating a
bad chest wall situation, I do not think that 33 unknown
deaths would cause any big change in our conclusion. 
Why did we remove the prosthesis at the beginning of the
experience? I think that, if you talk to Drs Pairolero and
Arnold, it was probably at the beginning and that was one fac-
tor, the inexperience of placing 3 Prolene prostheses in infect-
ed wounds; the 3 wounds got infected and the prostheses need-
ed to be removed. The confidence of the surgeons built up over
the years, and we discovered that we now can leave a PTFE
prosthesis in place. PTFE has become our prosthesis of choice
because it is impervious to air and fluid. It is easy to manipu-
late; it is easy to place in the chest wall; it has good rigidity, and
it does not wrinkle like Prolene material. On the other hand, I
think today in an infected wound, we could leave, in certain
circumstances, a PM. If it is well incorporated and the wound
is not completely falling apart, there is a chance that PM will
survive. We just do not use it at the present time. 
We certainly would not put a prosthesis, in any circum-
stances, in an infected wound. If we think that the stabiliza-
tion of the chest wall is needed, we will use a rib graft. We
will not use any foreign material in an infected wound.
We do not use omentum, but it is not a bad thing to use. It
is a great back-up but it is not our first choice. We have used
it 3 times. We think it is convenient to use the muscle of the
chest wall. It is always there; it is close to the incision; you
save an incision. 
What do we think of methyl methacrylate? We do not use
it and I do not think we will start. We know that other groups
had good experience, and we cannot say we have removed
many of those infected prostheses coming from outside,
although we have removed some. However, we have no expe-
rience placing methyl methacrylate. 
Dr G. Alexander Patterson (St Louis, Mo). There were 13
or 14 patients who underwent pneumonectomy, and there
were 8 postoperative deaths. How many of those patients
undergoing pneumonectomy died?
Dr Deschamps. Four. Pneumonectomy was a factor. One
half of the postoperative deaths occurred in patients who had
a pneumonectomy. 
Dr Mark K. Ferguson (Chicago, Ill). Could you give us
some idea of the technical factors involved in putting these
prostheses in? How much tension do you like to use, and how
do you get them attached to the ribs? 
The second question has to do with some of the patients
who had a single rib resected and yet apparently required
reconstruction. Did those patients have a sternectomy also?
Dr Deschamps. First we stretch the PTFE so that it looks
like a drum and feels like a drum. It is attached with a single
Prolene suture and in some cases a running suture to secure
the periphery of it. We try to go through the rib rather than
through the muscle only, because the muscle gets torn. We go
through the rib if we can with a large needle, or we pierce the
rib with a special punch to try to get the suture through the rib
and secure the PTFE patch solidly in the chest wall. We try to
stretch it like a drum. 
The patient from whom only 1 rib was removed had a ster-
nal resection, and it was considered a large sternal resection.
Even Dr Arnold will tell you that most sternal resections
alone do not necessitate a prosthesis. We have done some,
and those were in patients who underwent a sternal resection
and had a rib removed.
